Skip to main content
SYNAIRGEN PLC logo

SYNAIRGEN PLC — Investor Relations & Filings

Ticker · SNG ISIN · GB00B0381Z20 LEI · 213800IMMTOPPDF8HD24 IL Manufacturing
Open in API
Filings indexed 379 across all filing types
Latest filing 2025-01-16 AGM Information
Country GB United Kingdom
Listing IL SNG

About SYNAIRGEN PLC

https://www.synairgen.com/

Synairgen PLC is a clinical-stage biotechnology company focused on the discovery and development of treatments for severe respiratory diseases. The company's primary focus is its lead investigative candidate, SNG001, an inhaled formulation of interferon-beta (IFN-β). SNG001 is being developed as a potential host-directed, broad-spectrum antiviral therapy delivered directly to the lungs. This approach aims to treat hospitalized patients with severe viral lung infections caused by a range of pathogens, including influenza, RSV, and coronaviruses.

Recent filings

Filing Released Lang Actions
Result of General Meeting and Total Voting Rights
AGM Information Classification · 99% confidence The document is an official announcement released via RNS (Regulatory News Service) on January 16, 2025. The title explicitly states 'Result of General Meeting and Total Voting Rights'. It confirms that all resolutions presented at the General Meeting were duly passed. It also mentions the appointment of a new Non-Executive Director and provides an update on total voting rights following a share issuance. The content directly relates to the outcome of a shareholder vote, which aligns perfectly with the 'Declaration of Voting Results & Voting Rights Announcements' definition (DVA). Although it mentions a 'See separate announcement issued today announcing Martin's appointment' (MANG) and a future announcement regarding AIM cancellation (DLST/RPA), the primary focus and immediate subject of this specific filing is the result of the General Meeting.
2025-01-16 English
£18m raised to fund Phase 2 INVENT clinical trial
Share Issue/Capital Change Classification · 99% confidence The document is an official announcement released via RNS (RNS Number: 4977T, dated 15 January 2025). The content details the successful raising of £18 million through a subscription, which is explicitly stated as funding the Phase 2 INVENT clinical trial. This involves a significant financing activity (fundraising/subscription) and subsequent capital structure change (issuance of New Ordinary Shares conditional on a General Meeting). Since the core event is the announcement of securing financing to fund operations/trials, the most appropriate category is Capital/Financing Update (CAP). While it is distributed via RNS, the specific nature of the content (fundraising details) overrides the general RNS fallback. It is not a full 10-K, an ER, or a DIV notice.
2025-01-15 English
Proposed Fundraising
Capital/Financing Update Classification · 98% confidence The document is an RNS announcement (RNS Number : 8516Q) dated December 20, 2024. The primary subject is a 'Proposed Fundraising to raise a minimum of £18 million and a maximum of £19 million' involving a conditional subscription, a Placing, and an Open Offer. It also mentions a 'Proposed Waiver of Rule 9 of the City Code on Takeovers and Mergers' and confirms the posting of a Circular convening a General Meeting. Since the core purpose is announcing a significant capital raise (fundraising) involving the issuance of new shares, the most appropriate classification is Capital/Financing Update (CAP). Although it mentions a Circular for a General Meeting, the main focus is the financing structure and proceeds, not the AGM materials or voting results themselves.
2024-12-20 English
Exercise of Share Options and Total Voting Rights
Share Issue/Capital Change Classification · 99% confidence The document is a formal announcement disseminated via RNS (Regulatory News Service), indicated by the 'RNS Number' and the concluding boilerplate text referencing RNS and the London Stock Exchange. The content explicitly details the allotment of new ordinary shares following the exercise of share options by an ex-employee and provides the resulting total number of voting rights. This type of announcement, concerning changes in the number of shares in issue and voting rights, is a standard regulatory disclosure. Since it is a specific regulatory announcement that doesn't fit perfectly into categories like Share Issue (SHA) or Director's Dealing (DIRS), and it is clearly a regulatory filing distributed via the official channel (RNS), the most appropriate general classification is Regulatory Filings (RNS). Although it involves a share change, the primary function here is the mandatory notification of the resulting total share count, making RNS the best fit among the provided options for a general regulatory update.
2024-10-30 English
Results of AGM and Appointment of New Chairman
AGM Information Classification · 99% confidence The document explicitly states it announces the 'Results of Annual General Meeting' and confirms that 'All resolutions proposed at its Annual General Meeting were passed.' It also mentions the immediate succession of the Chairman post-AGM. This content directly relates to the proceedings and outcomes of the Annual General Meeting. Therefore, the most appropriate classification is AGM Information (AGM-R). Although it contains management changes (MANG), the primary focus and context are the AGM results.
2024-10-10 English
Interim Results
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim results for the six months ended 30 June 2024' and contains detailed financial statements, including a Statement of Comprehensive Income and a Statement of Financial Position, as well as an operational and financial review. It is a comprehensive report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2024
2024-09-26 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.